Company news

Novo Nordisk A/S news in 2025

Novo Nordisk A/S's news releases, calls and decks from 2025, newest first.

View company

Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent

December 31, 2025

Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage

December 24, 2025

FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults

December 22, 2025

Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management

December 22, 2025

Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management

December 18, 2025

Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing

December 16, 2025

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

December 12, 2025

Novo Nordisk has completed its acquisition of Akero Therapeutics

December 9, 2025

New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of Therapies Targeting Alzheimer's Pathobiology

December 4, 2025

Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors

December 3, 2025

Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg

November 26, 2025

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes

November 25, 2025

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression

November 24, 2025

9amHealth to Expand Access to Obesity Management Treatment through New Employer Health Benefits Offering

November 21, 2025

Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month

November 17, 2025

Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S

November 14, 2025

Team Novo Nordisk announce extended partnership with Novo Nordisk for five additional years

November 14, 2025

Novo Nordisk A/S: Candidate for the Board of Directors will not seek election

November 13, 2025

Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis

November 10, 2025

Novo Nordisk will not increase its proposal to acquire Metsera, Inc.

November 8, 2025

Fangzhou, Novo Nordisk Launch Initiative for AI-Powered Diabetes and Weight Management Solutions at CIIE

November 7, 2025

Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

November 6, 2025

Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost

November 6, 2025

Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications

November 5, 2025

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

November 5, 2025

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

November 5, 2025

Novo Nordisk submits updated proposal to acquire Metsera, Inc.

November 4, 2025

Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management

November 3, 2025

Metsera Receives Unsolicited Proposal from Novo Nordisk

October 30, 2025

Novo Nordisk submits proposal to acquire Metsera, Inc.

October 30, 2025

Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting

October 28, 2025

Novo Holdings to make changes to its Board of Directors

October 21, 2025

The Novo Nordisk Foundation proposes new candidates for election as members of the Board of Directors of Novo Nordisk A/S

October 21, 2025

Notice convening an Extraordinary General Meeting of Novo Nordisk A/S

October 21, 2025

Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors

October 21, 2025

Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025

October 20, 2025

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

October 17, 2025

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

October 15, 2025

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio

October 9, 2025

Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first once-weekly basal insulin treatment for adults with type 2 diabetes

September 29, 2025

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

September 29, 2025

Calls in 2025

Decks in 2025